Artrya Limited · ASX:AYA
Artrya — Investor Presentation (April 2023)
20 slides from Artrya's investor presentation, Apr 4, 2023
Slide 1: Investor Presentation
For personal use only Investor Presentation 4 April 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer of this presentation, nor has it verified any of the contents of this presentation. You must consider your own financial situation, objectives and needs and conduct your own IMPORTANT NOTICE independent investigations, assessments and enquiries, including obtaining in
Slide 3: Executive Summary
Executive Summary o Coronary Artery Disease – a leading cause of death globally - kills 9m people For personal use only every year o The leading cause of death, Vulnerable Plaque, is rarely reported Save lives o Current approaches of assessing coronary artery disease have failed to reduce heart atta
Slide 4: Global Problem
Global Problem Coronary Artery Disease is a leading cause of death globally For personal use only 126 $400 Every 13 One Nine million billion minutes third million people with heart disease costs Someone in of deaths globally CAD deaths significant the United States Australia dies of a are from heart
Slide 5: The culprit: Vulnerable Plaque
The culprit: Vulnerable Plaque Unstable soft plaque that ruptures -> causing clots to block arteries For personal use only 4% plaque burden = 5 x increased risk of heart attack1 BUILD UP OF PLAQUE VULNERABLE PLAQUE IS DIFFICULT TO SEE AND RARELY REPORTED. 5 © ARTRYA Private & Confidential © ARTRYA 1
Slide 6: Artrya Salix reports Vulnerable Plaque biomarker from a CCTA within minutes
Artrya Salix reports Vulnerable Plaque biomarker from a CCTA within minutes – a risk measure for a heart attack For personal use only 6 © ARTRYA Private & Confidential
Slide 7: Salix cuts overall scan-to-report time, reducing cost & with high accuracy at the point-of-care
Salix cuts overall scan-to-report time, reducing cost & with high accuracy at the point-of-care Salix Coronary Anatomy (SCA) For personal use only Automatically < 15 minutes Radiologist / Manual Image Radiographer Referring Patient CCTA Scan Cardiologist clinician Post-Processing Workup Assess and r
Slide 8: Salix cuts overall scan-to-report time, reducing cost & with high accuracy at the point-of-care
Salix cuts overall scan-to-report time, reducing cost & with high accuracy at the point-of-care For personal use only Improved quality • Standardised reports to international guidelines Reduced costs Reduced Improved • Improved consistency in • Salix is a cloud- costs quality findings and reporting
Slide 9: Salix delivers benefits to clinicians and patients from a single point-of-care solution
Salix delivers benefits to clinicians and patients from a single point-of-care solution For personal use only Radiographer Radiologist Cardiologist Patient Imaging Workflow Patient Improved Automation Optimisation Insight Outcomes • Artery tracking • Result automatically within • Rapid assessment •
Slide 10: The product and its development
The product and its development For personal use only Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. WHOLE HEART SEVERITY OPTIMISED VULNERABLE CHARACTERISATION PROCEDURE PATIENT Blood flow FOR CAD Vulnerable Patient assessment Procedure & Vulnerable Plaque
Slide 11: There are a number of factors that fuel a growth outlook for Artrya
There are a number of factors that fuel a growth outlook for Artrya For personal use only Europe • 375m CT scans globally North 17% each year America 25% • Increasing CT penetration in cardiac centers expected with reimbursement approvals in US Source: Frost & Sullivan Rest of World 19% APAC 39% USA
Slide 12: Artrya revenue generation
Artrya revenue generation For personal use only SaaS business model GLOBAL AVAILABILITY Freemium Pay-Go Charge a single flat fee 24/7 Market entry Access a free version Scalability per patient CCTA for a limited period analysed. HIGH GROSS MARGIN (TYPICAL SaaS MODEL) Significant uplift in Subscripti
Slide 13: Customer revenue generation (primarily USA)
Customer revenue generation (primarily USA) For personal use only Imaging provider Referring Cardiologist & Payers/Insurance Companies Hospitals • Reimbursement • Reduce costs through • New reimbursement incentivises reduce elimination of of US$900 for automated unnecessary angiograms unnecessary in
Slide 14: Product refinement & regulatory approval
Product refinement & regulatory approval STATUS For personal use only PILOT STUDIES REGULATORY APPROVALS Learnings from Australian pilot studies Australia Stability New Zealand Performance European CE Mark UK Conformity Assessment Accuracy FDA strategy implementation Ongoing Prestigious 2022 SCCT aw
Slide 15: Salix delivers additional benefits to that currently available on the market
Salix delivers additional benefits to that currently available on the market For personal use only Feature Artrya Salix Cleerly Coronary ElucidVivo Heartflow TeraRecon Automated Calcium ✓ ✕ ✕ ✕ ✓ Scoring Automated Stenosis ✓ ✓ Semi automated Semi automated Semi automated assessment (human in the loo
Slide 16: Summary
Summary For personal use only • Australian pilot site learnings incorporated into product • United Kingdom UKCA regulatory approval received • 4-year contract with UK National Health Service • European CE Mark regulatory approval received • FDA strategy being implemented • US$900 - $1,000 reimbursem
Slide 17: Appendix
Appendix For personal use only 17 © ARTRYA Private & Confidential
Slide 18: Our people – CEO and Board of Directors
Our people – CEO and Board of Directors For personal use only Chief Executive Officer Chair Non-Executive Director Non-Executive Director Mathew Regan Bernie Ridgeway Kate Hill Dr Jacque Sokolov 18 © ARTRYA Private & Confidential
Slide 19: Our people – Clinical Advisory Board
Our people – Clinical Advisory Board For personal use only Jacque Sokolov, MD Jacob Agris MD, PhD Jack Lewin, MD Professor Girish Dwivedi, MD Michael Ridner, MD Thomas Cheek, MD James C. Bonnette, MD Nicolas Chronos, MD Professor Benjamin Chow, MD 19 © ARTRYA Private & Confidential
Slide 20: Artrya – Financial & Trading Information
Artrya – Financial & Trading Information For personal use only • Cash balance $24.8m (end February) ASX: AYA Trading Chart • Average monthly net cash burn of $1.2m maintained ASX: AYA Trading Information Share Price (31 March 2023) $0.33 12 month low/high $0.215/$1.20 Top 5 Holders Shares outstandin